• No clinically available tests for risk stratification of complications due to high C5a complement levels are currently available. • Noninvasive method for determining an individual's risk for septic shock after exposure to an infectious agent. • Improvement on already commercially available tests .....
[更多]
Andreas H. Hielscher, Ph.D.
[更多]
Steven Marx, M.D.
[更多]
Shree Nayar, Ph.D.
[更多]
Amrita Sethi, MD.
[更多]
|< <- | [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] | -> >| |